UVA’s seed fund and corporate venturing unit PharmStandard Ventures featured in topical dry eye syndrome peptide spinout TearSolutions' financing round, taking its total to $21.5m.

TearSolutions, a US-based developer of topical dry eye syndrome therapies spun out of University of Virginia (UVA), has closed a $6.4m funding round backed by the $10m UVA Licensing and Ventures Group Seed Fund. The transaction, comprised of preferred stock and convertible promissory notes, was led by the Virginia Tech Carilion Innovation Fund, a VC…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.